Our Patient-Centered Mission Has Led Us Here
Chronic low back pain steals so much from life—and a type of this pain is called vertebrogenic pain. Thirty years of science and a strong foundation of clinical evidence has driven a clear understanding of vertebrogenic pain—and now our mission is to treat the millions of patients with this condition with the proven and durable Intracept Procedure.
Curious? Let’s live the proof of the Intracept Procedure together.
The Latest Living Proof
Relievant Medsystems Announces More Than 10,000 Patients Treated with the Intracept® Procedure for Vertebrogenic Low Back Pain
Treatment benchmark is the latest in a series of milestone accomplishments as the company continues raising awareness of vertebrogenic pain and expanding patient access to this proven therapy.
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
The Series G financing was led by new investor Ally Bridge Group with participation from existing investors Endeavour Vision, Vensana Capital, Lightstone Ventures, New Enterprise Associates, Canaan Partners and Morgenthaler Ventures.
Relievant Medsystems Receives 2023 Gallup Exceptional Workplace Award
Annual award recognizes companies that are dedicated to creating highly engaged workplace cultures and prioritizing employee engagement.
Looking for Proof?
Hear from the Ones Living It.
Real Intracept Procedure patients tell their stories of lasting relief from vertebrogenic pain.